Celgene Cp Cvr (CELGZ) 1.18 $CELGZ
FORMA Therapeutics Achieves Clinical Candidate Licensing Milestone for NASH Compound in Strategic Alliance with Celgene Corporation
BusinessWire - Wed Aug 31, 7:30AM CDT
FORMA Therapeutics (FORMA) announced today that they have successfully met their second preclinical development candidate milestone in their strategic collaboration agreement with Celgene Corporation, announced in April 2014, under which FORMA and Celgene will discover, develop and commercialize drug candidates.
CELGZ: 1.18 (+0.05)
FORMA Therapeutics Achieves Clinical Candidate Licensing Milestone for Nash Compound in Strategic Alliance with Celgene Corporation
BusinessWire - Wed Aug 31, 7:00AM CDT
FORMA Therapeutics (FORMA) announced today that they have successfully met their second preclinical development candidate milestone in their strategic collaboration agreement with Celgene Corporation, announced in April 2014, under which FORMA and Celgene will discover, develop and commercialize drug candidates.
CELGZ: 1.18 (+0.05)
Celgene Corporation to Webcast at Upcoming Investor Conferences and R&D Deep Dive in September
BusinessWire - Mon Aug 29, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences and at an R&D deep dive in September where Celgene management will provide an overview of the Company. The conferences and R&D deep dive will be webcast live and the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com.
CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Research Report on Biotech Equities -- Celgene, Sarepta Therapeutics, MannKind, and Opko Health
PR Newswire - Wed Aug 24, 6:35AM CDT
Stock-Callers.com has on its radar four Biotech stocks, namely: Celgene Corp. (NASDAQ: CELG), Sarepta Therapeutics Inc. (NASDAQ: SRPT), MannKind Corp. (NASDAQ: MNKD), and Opko Health Inc. (NASDAQ: OPK). According to Transparency Market Research, the global white biotechnology market will grow at a CAGR of 4.5% over the period between 2016 and 2024. White biotechnology, or industrial biotechnology, comprises all the biotechnology uses related to industrial processes. Learn more about these stocks by accessing their free research reports at:
OPK: 9.33 (+0.04), SRPT: 26.89 (+0.33), MNKD: 0.74 (unch), CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene, to Join Sorrento as Chief Medical Officer and President of Clinical Development
PR Newswire - Mon Aug 15, 8:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"
, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases, today announced that Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene Corporation (NASDAQ: CELG; "Celgene", has been appointed to the position of Chief Medical Officer and President of Clinical Development.
SRNE: 6.73 (-0.03), CELGZ: 1.18 (+0.05), CELG: 105.49 (-0.88)
Global Mitogen-Activated Protein Kinase 8 Pipeline Report 2016 - Celgene Corporation, Eisai Co., Ltd. & OPKO Health, Inc. - Research and Markets
BusinessWire - Fri Aug 12, 9:59AM CDT
Research and Markets has announced the addition of the "Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Pipeline Review, H1 2016" report to their offering.
OPK: 9.33 (+0.04), CELGZ: 1.18 (+0.05)
Cleave Biosciences Raises $37 Million Series B Financing
PR Newswire - Mon Aug 08, 6:30AM CDT
Cleave Biosciences today announced the completion of a $37 million Series B financing. The financing included the participation of new investors Celgene, Nextech Invest Ltd. and Arcus Ventures. Also participating in the round were Cleave's existing investors 5AM Ventures, Clarus Ventures, New Enterprise Associates (NEA), Orbimed Advisors, U.S. Venture Partners, Astellas Venture Management and Osage University Partners. The funds will be used to support further clinical development of CB-5083, the company's lead oncology drug candidate, and discovery efforts related to the company's AAA ATPase platform.
CELGZ: 1.18 (+0.05)
BetterInvesting Magazine Releases October Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use
PR Newswire - Fri Aug 05, 3:15PM CDT
The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Celgene Corporation (NDQ: CELG) as its October 2016 "Stock to Study" and Amgen Inc. (NDQ: AMGN), as its October 2016 "Undervalued Stock" for investors' informational and educational use.
AMGN: 169.77 (-0.36), CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Celgene Reports Second Quarter 2016 Operating and Financial Results
BusinessWire - Thu Jul 28, 6:30AM CDT
--- REVLIMID(R) Net Product Sales $1.7B in Q2:16; Increased 18% Y/Y
CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Learn how to target an 20% return on Chipotle Mexican Grill, or get option-trade ideas on Amgen, Celgene, Google Inc., and SolarEdge Technologies or any stock you choose
PR Newswire - Thu Jun 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMGN, CELG, CMG, GOOG, and SEDG.
SEDG: 17.32 (+0.49), CMG: 408.41 (-6.27), AMGN: 169.77 (-0.36), GOOGL: 796.87 (+5.47), GOOG: 771.46 (+2.68), CELGZ: 1.18 (+0.05), CELG: 105.49 (-0.88)
The Quest for an Effective Treatment for Pancreatic Cancer
ACCESSWIRE - Wed Jun 22, 7:16AM CDT
WINDSOR, ON / ACCESSWIRE / June 22, 2016 / The Wealthy Biotech Trader (or "WBT", an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight a couple of companies that we believe have immense potential in the quest for an effective pancreatic cancer treatment.
BLCM: 17.24 (-0.23), CELGZ: 1.18 (+0.05)
Global Stem Cell Therapy Market Worth USD 1.87 Billion by 2025 - Analysis, Technologies & Forecasts Report 2016-2025 - Key Vendors: Advanced Cell Technologies, Celgene Corp, Gamida Cell - Research and Markets
BusinessWire - Fri Jun 17, 11:26AM CDT
Research and Markets has announced the addition of the "Global Stem Cell Therapy Market Analysis & Trends - Industry Forecast to 2025" report to their offering.
CELGZ: 1.18 (+0.05)
Celgene Announces Additional $3 Billion Share Repurchase Authorization
BusinessWire - Wed Jun 15, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that during its June meeting the Company's Board of Directors authorized the repurchase of up to an additional $3.0 billion of the Company's common stock.
CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--in patients with beta-thalassemia -
XLRN: 30.84 (+0.59), CELGZ: 1.18 (+0.05)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--- Acceleron to host conference call and live webcast today at 8:00 a.m. EDT (2:00 p.m. CEST) -
XLRN: 30.84 (+0.59), CELGZ: 1.18 (+0.05), CELG: 105.49 (-0.88)
Celgene Announces Presentations of Investigational Studies in Blood Cancers at EHA 2016
BusinessWire - Thu Jun 09, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that more than 40 presentations reporting on investigational studies in blood cancers will be presented during the 21st European Hematology Association annual meeting in Copenhagen, Denmark, from June 9-12, 2016.
CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Study Reveals Racial Disparities in Multiple Myeloma Treatment Patterns
BusinessWire - Tue Jun 07, 3:05PM CDT
Celgene Corporation (NASDAQ:CELG) today announced the presentation of a study comparing treatment patterns, healthcare costs and overall survival between African American and Caucasian Medicare beneficiaries with newly diagnosed multiple myeloma. The study, which was presented by Dr. Sikander Ailawadhi of the Mayo Clinic at a poster session during the 52nd ASCO Annual Meeting in Chicago, Ill, discussed disparities observed in treatment initiation between the two studied populations and the impact of these disparities on patient outcomes.
CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Data Presented at ASCO 2016 Builds upon Foundation of Abraxane(R) Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer
BusinessWire - Sat Jun 04, 4:32PM CDT
Celgene Corporation (NASDAQ:CELG) today announced that results from multiple sponsored and independent studies presented during the 52nd ASCO Annual Meeting evaluated the use of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) in combination with gemcitabine in first-line metastatic pancreatic cancer.
CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Pooled Data from Meta-Analysis Suggest Significant Overall Survival Benefit of Investigational REVLIMID(R) Maintenance Following Autologous Stem Cell Transplant in Multiple Myeloma
BusinessWire - Fri Jun 03, 3:59PM CDT
Celgene Corporation (NASDAQ:CELG) today announced data from a meta-analysis of overall survival in multiple myeloma (MM) patients receiving investigational maintenance treatment with REVLIMID(R) (lenalidomide) capsules following high-dose melphalan and autologous stem cell transplant (ASCT) were presented during the 52nd ASCO Annual Meeting in Chicago, Illinois. The analysis, based on data from studies conducted by the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group
with support from the National Cancer Institute, Intergroupe Francophone du Myelome (IFM) and the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), was presented by Dr. Philip McCarthy of Roswell Park Cancer Institute and lead investigator of the CALGB (Alliance) 100104 study. The findings demonstrated significantly prolonged overall survival (OS) compared to the control arm of placebo or no maintenance.
CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Mylan Launches Generic Vidaza® Injection
PR Newswire - Thu Jun 02, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of Celgene's Vidaza® Injection, 100 mg/vial. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of the five French-American-British (FAB) subtypes of myelodysplastic syndrome, a blood cell disorder that can occur as a result of cancer treatments or can progress to leukemia.
MYL: 39.97 (-1.95), CELGZ: 1.18 (+0.05)
FORMA Therapeutics Achieves Clinical Candidate Licensing Milestone for NASH Compound in Strategic Alliance with Celgene Corporation
BusinessWire - Wed Aug 31, 7:30AM CDT
FORMA Therapeutics (FORMA) announced today that they have successfully met their second preclinical development candidate milestone in their strategic collaboration agreement with Celgene Corporation, announced in April 2014, under which FORMA and Celgene will discover, develop and commercialize drug candidates.
CELGZ: 1.18 (+0.05)
FORMA Therapeutics Achieves Clinical Candidate Licensing Milestone for Nash Compound in Strategic Alliance with Celgene Corporation
BusinessWire - Wed Aug 31, 7:00AM CDT
FORMA Therapeutics (FORMA) announced today that they have successfully met their second preclinical development candidate milestone in their strategic collaboration agreement with Celgene Corporation, announced in April 2014, under which FORMA and Celgene will discover, develop and commercialize drug candidates.
CELGZ: 1.18 (+0.05)
Celgene Corporation to Webcast at Upcoming Investor Conferences and R&D Deep Dive in September
BusinessWire - Mon Aug 29, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences and at an R&D deep dive in September where Celgene management will provide an overview of the Company. The conferences and R&D deep dive will be webcast live and the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com.
CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Research Report on Biotech Equities -- Celgene, Sarepta Therapeutics, MannKind, and Opko Health
PR Newswire - Wed Aug 24, 6:35AM CDT
Stock-Callers.com has on its radar four Biotech stocks, namely: Celgene Corp. (NASDAQ: CELG), Sarepta Therapeutics Inc. (NASDAQ: SRPT), MannKind Corp. (NASDAQ: MNKD), and Opko Health Inc. (NASDAQ: OPK). According to Transparency Market Research, the global white biotechnology market will grow at a CAGR of 4.5% over the period between 2016 and 2024. White biotechnology, or industrial biotechnology, comprises all the biotechnology uses related to industrial processes. Learn more about these stocks by accessing their free research reports at:
OPK: 9.33 (+0.04), SRPT: 26.89 (+0.33), MNKD: 0.74 (unch), CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene, to Join Sorrento as Chief Medical Officer and President of Clinical Development
PR Newswire - Mon Aug 15, 8:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"
, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases, today announced that Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene Corporation (NASDAQ: CELG; "Celgene", has been appointed to the position of Chief Medical Officer and President of Clinical Development. SRNE: 6.73 (-0.03), CELGZ: 1.18 (+0.05), CELG: 105.49 (-0.88)
Global Mitogen-Activated Protein Kinase 8 Pipeline Report 2016 - Celgene Corporation, Eisai Co., Ltd. & OPKO Health, Inc. - Research and Markets
BusinessWire - Fri Aug 12, 9:59AM CDT
Research and Markets has announced the addition of the "Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Pipeline Review, H1 2016" report to their offering.
OPK: 9.33 (+0.04), CELGZ: 1.18 (+0.05)
Cleave Biosciences Raises $37 Million Series B Financing
PR Newswire - Mon Aug 08, 6:30AM CDT
Cleave Biosciences today announced the completion of a $37 million Series B financing. The financing included the participation of new investors Celgene, Nextech Invest Ltd. and Arcus Ventures. Also participating in the round were Cleave's existing investors 5AM Ventures, Clarus Ventures, New Enterprise Associates (NEA), Orbimed Advisors, U.S. Venture Partners, Astellas Venture Management and Osage University Partners. The funds will be used to support further clinical development of CB-5083, the company's lead oncology drug candidate, and discovery efforts related to the company's AAA ATPase platform.
CELGZ: 1.18 (+0.05)
BetterInvesting Magazine Releases October Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use
PR Newswire - Fri Aug 05, 3:15PM CDT
The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Celgene Corporation (NDQ: CELG) as its October 2016 "Stock to Study" and Amgen Inc. (NDQ: AMGN), as its October 2016 "Undervalued Stock" for investors' informational and educational use.
AMGN: 169.77 (-0.36), CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Celgene Reports Second Quarter 2016 Operating and Financial Results
BusinessWire - Thu Jul 28, 6:30AM CDT
--- REVLIMID(R) Net Product Sales $1.7B in Q2:16; Increased 18% Y/Y
CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Learn how to target an 20% return on Chipotle Mexican Grill, or get option-trade ideas on Amgen, Celgene, Google Inc., and SolarEdge Technologies or any stock you choose
PR Newswire - Thu Jun 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMGN, CELG, CMG, GOOG, and SEDG.
SEDG: 17.32 (+0.49), CMG: 408.41 (-6.27), AMGN: 169.77 (-0.36), GOOGL: 796.87 (+5.47), GOOG: 771.46 (+2.68), CELGZ: 1.18 (+0.05), CELG: 105.49 (-0.88)
The Quest for an Effective Treatment for Pancreatic Cancer
ACCESSWIRE - Wed Jun 22, 7:16AM CDT
WINDSOR, ON / ACCESSWIRE / June 22, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight a couple of companies that we believe have immense potential in the quest for an effective pancreatic cancer treatment. BLCM: 17.24 (-0.23), CELGZ: 1.18 (+0.05)
Global Stem Cell Therapy Market Worth USD 1.87 Billion by 2025 - Analysis, Technologies & Forecasts Report 2016-2025 - Key Vendors: Advanced Cell Technologies, Celgene Corp, Gamida Cell - Research and Markets
BusinessWire - Fri Jun 17, 11:26AM CDT
Research and Markets has announced the addition of the "Global Stem Cell Therapy Market Analysis & Trends - Industry Forecast to 2025" report to their offering.
CELGZ: 1.18 (+0.05)
Celgene Announces Additional $3 Billion Share Repurchase Authorization
BusinessWire - Wed Jun 15, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that during its June meeting the Company's Board of Directors authorized the repurchase of up to an additional $3.0 billion of the Company's common stock.
CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--in patients with beta-thalassemia -
XLRN: 30.84 (+0.59), CELGZ: 1.18 (+0.05)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--- Acceleron to host conference call and live webcast today at 8:00 a.m. EDT (2:00 p.m. CEST) -
XLRN: 30.84 (+0.59), CELGZ: 1.18 (+0.05), CELG: 105.49 (-0.88)
Celgene Announces Presentations of Investigational Studies in Blood Cancers at EHA 2016
BusinessWire - Thu Jun 09, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that more than 40 presentations reporting on investigational studies in blood cancers will be presented during the 21st European Hematology Association annual meeting in Copenhagen, Denmark, from June 9-12, 2016.
CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Study Reveals Racial Disparities in Multiple Myeloma Treatment Patterns
BusinessWire - Tue Jun 07, 3:05PM CDT
Celgene Corporation (NASDAQ:CELG) today announced the presentation of a study comparing treatment patterns, healthcare costs and overall survival between African American and Caucasian Medicare beneficiaries with newly diagnosed multiple myeloma. The study, which was presented by Dr. Sikander Ailawadhi of the Mayo Clinic at a poster session during the 52nd ASCO Annual Meeting in Chicago, Ill, discussed disparities observed in treatment initiation between the two studied populations and the impact of these disparities on patient outcomes.
CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Data Presented at ASCO 2016 Builds upon Foundation of Abraxane(R) Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer
BusinessWire - Sat Jun 04, 4:32PM CDT
Celgene Corporation (NASDAQ:CELG) today announced that results from multiple sponsored and independent studies presented during the 52nd ASCO Annual Meeting evaluated the use of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) in combination with gemcitabine in first-line metastatic pancreatic cancer.
CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Pooled Data from Meta-Analysis Suggest Significant Overall Survival Benefit of Investigational REVLIMID(R) Maintenance Following Autologous Stem Cell Transplant in Multiple Myeloma
BusinessWire - Fri Jun 03, 3:59PM CDT
Celgene Corporation (NASDAQ:CELG) today announced data from a meta-analysis of overall survival in multiple myeloma (MM) patients receiving investigational maintenance treatment with REVLIMID(R) (lenalidomide) capsules following high-dose melphalan and autologous stem cell transplant (ASCT) were presented during the 52nd ASCO Annual Meeting in Chicago, Illinois. The analysis, based on data from studies conducted by the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group
with support from the National Cancer Institute, Intergroupe Francophone du Myelome (IFM) and the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), was presented by Dr. Philip McCarthy of Roswell Park Cancer Institute and lead investigator of the CALGB (Alliance) 100104 study. The findings demonstrated significantly prolonged overall survival (OS) compared to the control arm of placebo or no maintenance. CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)
Mylan Launches Generic Vidaza® Injection
PR Newswire - Thu Jun 02, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of Celgene's Vidaza® Injection, 100 mg/vial. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of the five French-American-British (FAB) subtypes of myelodysplastic syndrome, a blood cell disorder that can occur as a result of cancer treatments or can progress to leukemia.
MYL: 39.97 (-1.95), CELGZ: 1.18 (+0.05)
